These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 30809306)

  • 1. Lectin-Mediated pH-Sensitive Doxorubicin Prodrug for Pre-Targeted Chemotherapy of Colorectal Cancer with Enhanced Efficacy and Reduced Side Effects.
    Yao M; Ma X; Zhang X; Shi L; Liu T; Liang X; Zhao H; Li X; Li L; Gao H; Jia B; Wang F
    Theranostics; 2019; 9(3):747-760. PubMed ID: 30809306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine.
    Hong Y; Che S; Hui B; Yang Y; Wang X; Zhang X; Qiang Y; Ma H
    Biomed Pharmacother; 2019 Apr; 112():108614. PubMed ID: 30798129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin/heparin composite nanoparticles for caspase-activated prodrug chemotherapy.
    Khaliq NU; Sandra FC; Park DY; Lee JY; Oh KS; Kim D; Byun Y; Kim IS; Kwon IC; Kim SY; Yuk SH
    Biomaterials; 2016 Sep; 101():131-42. PubMed ID: 27286189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery.
    Bao Y; Yin M; Hu X; Zhuang X; Sun Y; Guo Y; Tan S; Zhang Z
    J Control Release; 2016 Aug; 235():182-194. PubMed ID: 27264552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy.
    Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G
    Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy.
    Sun J; Liu Y; Chen Y; Zhao W; Zhai Q; Rathod S; Huang Y; Tang S; Kwon YT; Fernandez C; Venkataramanan R; Li S
    J Control Release; 2017 Jul; 258():43-55. PubMed ID: 28501705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-targeted and stimulus-responsive polymeric prodrug nanoparticles to enhance the anticancer therapeutic efficacy of doxorubicin.
    Kim N; Kwon S; Kwon G; Song N; Jo H; Kim C; Park S; Lee D
    J Control Release; 2024 May; 369():351-362. PubMed ID: 38552963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
    Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
    Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects.
    Lages EB; Fernandes RS; Andrade MMS; Paiyabhroma N; de Oliveira RB; Fernandes C; Cassali GD; Sicard P; Richard S; Branco de Barros AL; Ferreira LAM
    Biomed Pharmacother; 2021 Dec; 144():112373. PubMed ID: 34794238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-targeted and pH-sensitive Doxorubicin Prodrug-Microbubble Complex with Ultrasound for Tumor Treatment.
    Luo W; Wen G; Yang L; Tang J; Wang J; Wang J; Zhang S; Zhang L; Ma F; Xiao L; Wang Y; Li Y
    Theranostics; 2017; 7(2):452-465. PubMed ID: 28255342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-Sensitive Charge-Conversional Polymeric Prodrug for Efficient Codelivery of Demethylcantharidin and Doxorubicin.
    Wu Y; Zhou D; Zhang Q; Xie Z; Chen X; Jing X; Huang Y
    Biomacromolecules; 2016 Aug; 17(8):2650-61. PubMed ID: 27384255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Evaluation of an Epidermal Growth Factor Receptor-Targeted Doxorubicin-Peptide Conjugate: Toxicity, Biodistribution, and Efficacy in Mice.
    Yang F; Ai W; Jiang F; Liu X; Huang Z; Ai S
    J Pharm Sci; 2016 Feb; 105(2):639-649. PubMed ID: 26869425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-specific delivery of doxorubicin through conjugation of pH-responsive peptide for overcoming drug resistance in cancer.
    Feng C; Rui M; Shen H; Xin Y; Zhang J; Li J; Yue L; Lai W; Xu X
    Int J Pharm; 2017 Aug; 528(1-2):322-333. PubMed ID: 28606508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced anti-tumor effect of pH-responsive dextrin nanogels delivering doxorubicin on colorectal cancer.
    Manchun S; Dass CR; Cheewatanakornkool K; Sriamornsak P
    Carbohydr Polym; 2015 Aug; 126():222-30. PubMed ID: 25933543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy.
    Hou M; Gao YE; Shi X; Bai S; Ma X; Li B; Xiao B; Xue P; Kang Y; Xu Z
    Acta Biomater; 2018 Sep; 77():228-239. PubMed ID: 30006314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailor-made legumain/pH dual-responsive doxorubicin prodrug-embedded nanoparticles for efficient anticancer drug delivery and in situ monitoring of drug release.
    Li Y; Niu Y; Zhu J; Gao C; Xu Q; He Z; Chen D; Xu M; Liu Y
    Nanoscale; 2020 Jan; 12(4):2673-2685. PubMed ID: 31942900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acid-responsive PEGylated doxorubicin prodrug nanoparticles for neuropilin-1 receptor-mediated targeted drug delivery.
    Song H; Zhang J; Wang W; Huang P; Zhang Y; Liu J; Li C; Kong D
    Colloids Surf B Biointerfaces; 2015 Dec; 136():365-74. PubMed ID: 26433349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
    J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.